What is Protai?
Founded in 2021 and headquartered in Tel Aviv, Israel, Protai is at the forefront of revolutionizing drug discovery. By integrating advanced proteomics with artificial intelligence, the company aims to uncover novel biological insights crucial for combating complex diseases. This strategic application of technology positions Protai to accelerate the development of new therapeutic solutions.
How much funding has Protai raised?
Protai has raised a total of $20M across 2 funding rounds:
Angel/Seed
$8M
Angel/Seed
$12M
Angel/Seed (2022): $8M with participation from Grove Ventures Ltd and Pitango HealthTech
Angel/Seed (2023): $12M led by Grove Ventures Ltd
Key Investors in Protai
Grove Ventures Ltd
Grove Ventures is a leading early-stage venture capital investment firm with over half-a-billion dollars under management. The company partners early with exceptional Israeli entrepreneurs who believe that the Deep Future is now and are ready to build it.Grove Ventures is headquartered in Tel Aviv-Yafo, Israel.
Pitango HealthTech
Pitango HealthTech is an investment firm focused on advancing healthcare technologies. Their participation suggests a strategic interest in Protai's innovative approach to drug discovery.
Undisclosed Investor
An undisclosed investor participated in this funding round, indicating potential strategic alignment or a desire for privacy in their investment activities.
What's next for Protai?
With substantial backing and a clear focus on leveraging AI and proteomics for drug discovery, Protai is poised for significant growth. The recent major strategic investment signals confidence from its backers in the company's potential to disrupt the pharmaceutical industry. Future endeavors will likely involve expanding research and development capabilities, forging strategic partnerships, and advancing its pipeline of potential drug candidates through clinical trials, ultimately aiming to bring innovative treatments to market.
See full Protai company page
